California State Teachers Retirement System Boosts Position in Exelixis, Inc. (EXEL)
California State Teachers Retirement System boosted its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 14.9% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 515,076 shares of the biotechnology company’s stock after buying an additional 66,783 shares during the period. California State Teachers Retirement System owned approximately 0.18% of Exelixis worth $12,686,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. First Quadrant L P CA purchased a new position in Exelixis in the second quarter valued at approximately $144,000. Wetherby Asset Management Inc. purchased a new position in Exelixis in the second quarter valued at approximately $218,000. Caxton Associates LP purchased a new position in Exelixis in the second quarter valued at approximately $227,000. Capstone Asset Management Co. purchased a new position in Exelixis in the second quarter valued at approximately $242,000. Finally, Cigna Investments Inc. New purchased a new position in Exelixis in the second quarter valued at approximately $243,000. Hedge funds and other institutional investors own 79.20% of the company’s stock.
Several research analysts recently commented on EXEL shares. Zacks Investment Research upgraded shares of Exelixis from a “hold” rating to a “strong-buy” rating and set a $28.00 price target on the stock in a report on Tuesday, July 4th. BidaskClub upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Friday, August 25th. Deutsche Bank AG lowered shares of Exelixis from a “buy” rating to a “hold” rating and raised their price target for the company from $26.00 to $29.00 in a report on Thursday, August 3rd. Stifel Nicolaus restated a “hold” rating and issued a $26.00 price target on shares of Exelixis in a report on Thursday, September 7th. Finally, SunTrust Banks, Inc. started coverage on shares of Exelixis in a report on Thursday, July 13th. They issued a “buy” rating and a $33.00 price target on the stock. Six analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Exelixis has an average rating of “Buy” and an average target price of $31.38.
ILLEGAL ACTIVITY WARNING: “California State Teachers Retirement System Boosts Position in Exelixis, Inc. (EXEL)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/21/california-state-teachers-retirement-system-boosts-position-in-exelixis-inc-exel.html.
Shares of Exelixis, Inc. (NASDAQ EXEL) opened at 27.17 on Friday. The stock has a market cap of $7.99 billion, a price-to-earnings ratio of 137.22 and a beta of 1.91. Exelixis, Inc. has a 1-year low of $10.04 and a 1-year high of $29.50. The stock’s 50 day moving average is $26.26 and its 200-day moving average is $24.14.
Exelixis (NASDAQ:EXEL) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.02. Exelixis had a return on equity of 80.43% and a net margin of 18.20%. The firm had revenue of $99.01 million during the quarter, compared to analyst estimates of $85.27 million. During the same period in the previous year, the company earned ($0.15) EPS. The company’s revenue for the quarter was up 173.1% on a year-over-year basis. On average, analysts anticipate that Exelixis, Inc. will post $0.28 EPS for the current year.
In related news, EVP Jeffrey Hessekiel sold 27,302 shares of the business’s stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $24.28, for a total value of $662,892.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Christopher J. Senner sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $26.79, for a total value of $2,679,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 970,152 shares of company stock valued at $25,923,457. Corporate insiders own 5.10% of the company’s stock.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Stock Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related stocks with our FREE daily email newsletter.